{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:20:38Z","timestamp":1772119238765,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82220108004"],"award-info":[{"award-number":["82220108004"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04121-0","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:31:58Z","timestamp":1753252318000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multifunctional T-cell engager containing CD80 enhances prostate cancer treatment"],"prefix":"10.1007","volume":"74","author":[{"given":"Disen","family":"Nie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"issue":"3","key":"4121_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"4121_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdv209","volume":"26","author":"L Apetoh","year":"2015","unstructured":"Apetoh L, Ladoire S, Coukos G et al (2015) Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol 26(9):1813\u20131823","journal-title":"Ann Oncol"},{"issue":"11","key":"4121_CR3","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20(11):651\u2013668","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"4121_CR4","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"4121_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M et al (2020) Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol 38(5):395\u2013405","journal-title":"J Clin Oncol"},{"issue":"6","key":"4121_CR6","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s12325-022-02085-6","volume":"39","author":"JM Hafron","year":"2022","unstructured":"Hafron JM, Wilfehrt HM, Ferro C et al (2022) Real-world effectiveness of sipuleucel-T on overall survival in men with advanced prostate cancer treated with androgen receptor-targeting agents. Adv Ther 39(6):2515\u20132532","journal-title":"Adv Ther"},{"issue":"5","key":"4121_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006794","volume":"11","author":"DE Reed-Perino","year":"2023","unstructured":"Reed-Perino DE, Lai M, Yu EY et al (2023) Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report. J Immunother Cancer 11(5):e006794","journal-title":"J Immunother Cancer"},{"issue":"5","key":"4121_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.eururo.2018.02.007","volume":"73","author":"AD Lamb","year":"2018","unstructured":"Lamb AD, Bryant RJ, Mills IG et al (2018) First report of prostate-specific membrane antigen-targeted immunotherapy in prostate cancer: the future is bright. Eur Urol 73(5):653\u2013655","journal-title":"Eur Urol"},{"issue":"1","key":"4121_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00262-007-0348-6","volume":"57","author":"P B\u00fchler","year":"2008","unstructured":"B\u00fchler P, Wolf P, Gierschner D et al (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol Immunother 57(1):43\u201352","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"4121_CR10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1158\/1535-7163.MCT-15-0242","volume":"15","author":"G Hernandez-Hoyos","year":"2016","unstructured":"Hernandez-Hoyos G, Sewell T, Bader R et al (2016) MOR209\/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer. Mol Cancer Ther 15(9):2155\u20132165","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"4121_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/pros.21274","volume":"71","author":"K Fortm\u00fcller","year":"2011","unstructured":"Fortm\u00fcller K, Alt K, Gierschner D et al (2011) Effective targeting of prostate cancer by lymphocytes redirected by a PSMA \u00d7 CD3 bispecific single-chain diabody. Prostate 71(6):588\u2013596","journal-title":"Prostate"},{"issue":"12","key":"4121_CR12","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-12-0042","volume":"11","author":"M Friedrich","year":"2012","unstructured":"Friedrich M, Raum T, Lutterbuese R et al (2012) Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 11(12):2664\u20132673","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"4121_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2326-6066.CIR-19-0518","volume":"8","author":"D Chiu","year":"2020","unstructured":"Chiu D, Tavar\u00e9 R, Haber L et al (2020) A PSMA-targeting CD3 bispecific antibody induces antitumor responses that are enhanced by 4\u20131BB costimulation. Cancer Immunol Res 8(5):596\u2013608","journal-title":"Cancer Immunol Res"},{"issue":"525","key":"4121_CR14","doi-asserted-by":"publisher","first-page":"7888","DOI":"10.1126\/scitranslmed.aaw7888","volume":"12","author":"D Skokos","year":"2020","unstructured":"Skokos D, Waite JC, Haber L et al (2020) A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med 12(525):7888","journal-title":"Sci Transl Med"},{"issue":"6440","key":"4121_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aav7062","volume":"364","author":"D Sugiura","year":"2019","unstructured":"Sugiura D, Maruhashi T, Okazaki IM et al (2019) Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses. Science 364(6440):558\u2013566","journal-title":"Science"},{"issue":"8","key":"4121_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1089\/hum.2013.051","volume":"24","author":"W Li","year":"2013","unstructured":"Li W, Fan D, Yang M et al (2013) Cytosine arabinoside promotes cytotoxic effect of T cells on leukemia cells mediated by bispecific antibody. Hum Gene Ther 24(8):751\u2013760","journal-title":"Hum Gene Ther"},{"issue":"37","key":"4121_CR17","doi-asserted-by":"publisher","first-page":"59471","DOI":"10.18632\/oncotarget.10697","volume":"7","author":"D Han","year":"2016","unstructured":"Han D, Wu J, Han Y et al (2016) A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer. Oncotarget 7(37):59471\u201359481","journal-title":"Oncotarget"},{"issue":"2","key":"4121_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.V79.2.489.489","volume":"79","author":"GJ Freeman","year":"1992","unstructured":"Freeman GJ, Disteche CM, Gribben JG et al (1992) The gene for B7, a costimulatory signal for T-cell activation, maps to chromosomal region 3q13.3\u20133q21. Blood 79(2):489\u2013494","journal-title":"Blood"},{"issue":"9","key":"4121_CR19","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.3389\/fimmu.2018.03124","volume":"30","author":"LW Treffers","year":"2019","unstructured":"Treffers LW, van Houdt M, Bruggeman CW et al (2019) Fc\u03b3RIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front Immunol 30(9):3124","journal-title":"Front Immunol"},{"key":"4121_CR20","unstructured":"The results shown in the article are in whole or part based upon data generated by the TCGA Research Network: https:\/\/www.cancer.gov\/tcga"},{"issue":"608","key":"4121_CR21","doi-asserted-by":"publisher","first-page":"eabd1524","DOI":"10.1126\/scitranslmed.abd1524","volume":"13","author":"B Belmontes","year":"2021","unstructured":"Belmontes B, Sawant DV, Zhong W et al (2021) Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci Transl Med 13(608):eabd1524","journal-title":"Sci Transl Med"},{"issue":"7","key":"4121_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","volume":"17","author":"ME Goebeler","year":"2020","unstructured":"Goebeler ME, Bargou RC (2020) T cell-engaging therapies-BiTEs and beyond. Nat Rev Clin Oncol 17(7):418\u2013434","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04121-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04121-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04121-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:53:37Z","timestamp":1757274817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04121-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":22,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["4121"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04121-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5391004\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no competing interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"274"}}